Acuitas Therapeutics is a private biotechnology company specializing in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. Acuitas partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical trials and the marketplace. The team works with global partners to develop new therapies to address unmet clinical needs based on the internationally recognized capabilities of its proprietary delivery technology. Acuitas Therapeutics’ lipid nanoparticle technology is used in the Pfizer/BioNTech COVID-19 vaccine COMIRNATY®. The Acuitas team is currently working on therapeutics focused on addressing cancer, HIV/AIDS, tuberculosis, malaria, rabies and other serious diseases.